Halozyme Therapeutics vs US Dollar/Swiss Franc FX Spot Rate: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Halozyme Therapeutics Inc (HALO)

Q3 202615 Jul – 8 Oct 2026

▲3▼1

Halozyme Q3: Strong Earnings, New Deals, Legal Win, But Dilution Risk

Q2 Earnings Beat and Guidance Raise Halozyme reported Q2 revenue of $481 million, up 48% from a year earlier, and raised its full-year guidance. The stock hit a 52-week high as investors cheered the strong results and brighter outlook.
This is the core financial performance that directly drove the stock higher during the quarter.
New ENHANZE Partnerships and Expanded Collaboration Halozyme signed new ENHANZE deals with Incyte, Vertex, and GSK, and expanded its existing collaboration with argenx. These agreements broaden future royalty streams, giving investors more confidence in long-term revenue growth.
New partnerships are a key growth driver and were a major positive catalyst during the quarter.
Legal Win and Positive Trial Data A Dutch court blocked Merck’s subcutaneous Keytruda for patent infringement, potentially adding royalties or damages for Halozyme. Also, positive Darzalex Faspro trial data support long-term royalties, reinforcing the company’s intellectual property strength.
These legal and clinical developments protect and enhance future revenue streams, directly impacting investor sentiment.
Convertible Notes Raise Creates Dilution Risk Halozyme raised $1.3 billion in convertible notes, strengthening its balance sheet but potentially diluting shares if the stock price rises above the conversion price. This is a risk that could weigh on the stock if not managed carefully.
This is a significant counterweight to the positive news, as dilution can pressure the stock price.

September 202615 Aug – 8 Oct 2026

▲3

Halozyme's Royalty Engine Roars as Legal Wins and Deals Pile Up

Q2 Beat and Raised Guidance Halozyme's Q2 revenue jumped 48% to $481 million, beating estimates, and the company raised full-year guidance. This shows its royalty business is growing faster than expected, which directly boosts investor confidence and the stock price.
This is the core fundamental driver of the stock's recent surge and answers why HALO is moving.
New ENHANZE Deals Expand Royalty Stream Halozyme signed five new collaborations, including with Vertex, GSK, and Incyte, and expanded its argenx deal from six to eight targets. More partners mean more future milestone payments and royalties, which supports long-term revenue growth and lifts the stock.
New deals are a key growth catalyst that directly increases future royalty revenue.
Dutch Court Blocks Merck's Keytruda SC A Dutch court ruled that Merck's subcutaneous Keytruda infringes Halozyme's patent, banning sales in eight European markets. This legal win protects Halozyme's technology and could lead to royalties or damages from Merck, boosting the stock.
This is a major legal victory that validates Halozyme's patent portfolio and could unlock significant value.
Upsized Convertible Notes Offering Halozyme raised $1.3 billion in convertible notes to refinance older debt. While this strengthens the balance sheet and funds growth, it also creates potential future dilution if the stock rises above the conversion price, which can weigh on shares.
This financing event affects the capital structure and has both positive and negative implications for the stock.

Latest15 Aug – 8 Oct 2026

▲3

Halozyme's Royalty Engine Roars as Legal Wins and Deals Pile Up

Q2 Beat and Raised Guidance Halozyme's Q2 revenue jumped 48% to $481 million, beating estimates, and the company raised full-year guidance. This shows its royalty business is growing faster than expected, which directly boosts investor confidence and the stock price.
This is the core fundamental driver of the stock's recent surge and answers why HALO is moving.
New ENHANZE Deals Expand Royalty Stream Halozyme signed five new collaborations, including with Vertex, GSK, and Incyte, and expanded its argenx deal from six to eight targets. More partners mean more future milestone payments and royalties, which supports long-term revenue growth and lifts the stock.
New deals are a key growth catalyst that directly increases future royalty revenue.
Dutch Court Blocks Merck's Keytruda SC A Dutch court ruled that Merck's subcutaneous Keytruda infringes Halozyme's patent, banning sales in eight European markets. This legal win protects Halozyme's technology and could lead to royalties or damages from Merck, boosting the stock.
This is a major legal victory that validates Halozyme's patent portfolio and could unlock significant value.
Upsized Convertible Notes Offering Halozyme raised $1.3 billion in convertible notes to refinance older debt. While this strengthens the balance sheet and funds growth, it also creates potential future dilution if the stock rises above the conversion price, which can weigh on shares.
This financing event affects the capital structure and has both positive and negative implications for the stock.

July 202615 Jul – 14 Aug 2026

▲4

Halozyme's Q2 Beat and New Incyte Deal Drive Growth Story

Q2 earnings beat and raised guidance Halozyme reported Q2 revenue of $481 million, up 48% from a year ago, and raised its full-year revenue outlook to $1.835–$1.910 billion. The stock jumped 20% on the news, as investors saw stronger demand for its drug-delivery technology and better profit potential.
This is the biggest new financial event, directly boosting investor confidence and the stock price.
New Incyte collaboration for ENHANZE Halozyme signed a global licensing deal with Incyte to use its ENHANZE technology with an experimental cancer drug. Halozyme gets upfront cash, potential milestone payments, and future royalties. This expands its partner base and adds a new stream of income without major new spending.
This is a fresh partnership that adds future revenue and validates Halozyme's technology platform.
Positive trial results for Darzalex Faspro A late-stage trial showed that Darzalex Faspro, which uses Halozyme's ENHANZE technology, combined with J&J's Talvey significantly improved survival in multiple myeloma patients. This supports continued adoption of the drug, meaning more royalties for Halozyme over time.
It reinforces demand for an existing partnered product, which drives recurring royalty revenue.
Stock hits 52-week high on momentum Halozyme shares reached a 52-week high of $103.30 after the strong earnings and guidance. The stock has risen 46% over the past year, reflecting growing investor confidence in its business model and cash generation.
This captures the market's positive reaction and momentum, which can attract more investors.

15 Jul – 14 Aug 2026

▲4

Halozyme's Q2 Beat and New Incyte Deal Drive Growth Story

Q2 earnings beat and raised guidance Halozyme reported Q2 revenue of $481 million, up 48% from a year ago, and raised its full-year revenue outlook to $1.835–$1.910 billion. The stock jumped 20% on the news, as investors saw stronger demand for its drug-delivery technology and better profit potential.
This is the biggest new financial event, directly boosting investor confidence and the stock price.
New Incyte collaboration for ENHANZE Halozyme signed a global licensing deal with Incyte to use its ENHANZE technology with an experimental cancer drug. Halozyme gets upfront cash, potential milestone payments, and future royalties. This expands its partner base and adds a new stream of income without major new spending.
This is a fresh partnership that adds future revenue and validates Halozyme's technology platform.
Positive trial results for Darzalex Faspro A late-stage trial showed that Darzalex Faspro, which uses Halozyme's ENHANZE technology, combined with J&J's Talvey significantly improved survival in multiple myeloma patients. This supports continued adoption of the drug, meaning more royalties for Halozyme over time.
It reinforces demand for an existing partnered product, which drives recurring royalty revenue.
Stock hits 52-week high on momentum Halozyme shares reached a 52-week high of $103.30 after the strong earnings and guidance. The stock has risen 46% over the past year, reflecting growing investor confidence in its business model and cash generation.
This captures the market's positive reaction and momentum, which can attract more investors.

US Dollar/Swiss Franc FX Spot Rate (USDCHF.FOREX)

Q3 202618 Jun – 8 Oct 2026

▲2▼2

SNB Dovishness Lifts USD/CHF Despite Safe-Haven Franc Demand

SNB holds rates at zero, signals readiness to weaken franc The Swiss National Bank kept interest rates at zero and indicated it was ready to weaken the franc, which supported USD/CHF by making the franc less attractive to hold.
This policy stance was a key force pushing USD/CHF higher during the period.
Fed rate-hike expectations and safe-haven dollar demand Expectations that the Federal Reserve might raise rates, along with safe-haven demand for the dollar due to US-Iran tensions, supported USD/CHF by making the dollar more attractive.
These factors contributed to USD/CHF strength, especially in the first half of the period.
Weak US data and AI-driven hedging flows favouring franc Weak US jobs and inflation data, dovish Fed comments, and AI-driven hedging flows that favoured the franc pushed USD/CHF down to around 0.8034, showing that not all forces pointed in the same direction.
This explains the downward pressure on USD/CHF during the period.
Safe-haven franc demand and rising Swiss inflation Safe-haven demand for the franc from geopolitical and Eurozone fiscal worries, plus rising Swiss inflation that fuelled rate-hike bets, could strengthen the franc and push USD/CHF lower.
These counterweights limited USD/CHF gains and highlight risks to the upward trend.

August 202613 Jul – 8 Oct 2026

▲2▼2

SNB Dovishness and Safe-Haven Flows Shape USD/CHF

SNB Holds Rates, Strikes Dovish Tone The Swiss National Bank kept its policy rate at 0% and softened its language on currency intervention, signaling it is comfortable with a weaker franc. This drove the franc down broadly, pushing USD/CHF to its highest since May 2025. A dovish SNB reduces the franc's appeal, strengthening the dollar against it.
This is the dominant new driver: the SNB's dovish hold directly weakened the franc and lifted USD/CHF to multi-month highs.
SNB Pushback Against Rate Hike Expectations SNB Vice Chairman Martin said there is no need to adjust monetary policy despite inflation rising to 1.0%, the highest in over two years. This pushed back against market bets for a December rate hike, weakening the franc further. Lower expected Swiss rates make the franc less attractive versus the dollar.
This reinforces the SNB's dovish stance and directly counters rate-hike expectations, adding downward pressure on the franc.
Safe-Haven Demand Supports Franc Geopolitical tensions and Eurozone fiscal worries are driving investors to the Swiss franc as a safe haven. Rabobank expects EUR/CHF to hold near 0.93 due to this demand. Strong safe-haven flows increase demand for francs, which strengthens the franc and pushes USD/CHF down.
This is the main counterweight: safe-haven demand for the franc limits USD/CHF's rise despite SNB dovishness.
Swiss Inflation Fuels Rate Hike Bets Swiss August inflation doubled to 0.8% year-on-year, exceeding expectations and raising the chance of an earlier SNB rate hike. Higher expected Swiss rates would strengthen the franc. This is a counterforce to the SNB's dovish stance and could push USD/CHF lower if hike bets grow.
This is a key risk to the positive USD/CHF trend: rising inflation could force the SNB to hike, boosting the franc.

Latest13 Jul – 8 Oct 2026

▲2▼2

SNB Dovishness and Safe-Haven Flows Shape USD/CHF

SNB Holds Rates, Strikes Dovish Tone The Swiss National Bank kept its policy rate at 0% and softened its language on currency intervention, signaling it is comfortable with a weaker franc. This drove the franc down broadly, pushing USD/CHF to its highest since May 2025. A dovish SNB reduces the franc's appeal, strengthening the dollar against it.
This is the dominant new driver: the SNB's dovish hold directly weakened the franc and lifted USD/CHF to multi-month highs.
SNB Pushback Against Rate Hike Expectations SNB Vice Chairman Martin said there is no need to adjust monetary policy despite inflation rising to 1.0%, the highest in over two years. This pushed back against market bets for a December rate hike, weakening the franc further. Lower expected Swiss rates make the franc less attractive versus the dollar.
This reinforces the SNB's dovish stance and directly counters rate-hike expectations, adding downward pressure on the franc.
Safe-Haven Demand Supports Franc Geopolitical tensions and Eurozone fiscal worries are driving investors to the Swiss franc as a safe haven. Rabobank expects EUR/CHF to hold near 0.93 due to this demand. Strong safe-haven flows increase demand for francs, which strengthens the franc and pushes USD/CHF down.
This is the main counterweight: safe-haven demand for the franc limits USD/CHF's rise despite SNB dovishness.
Swiss Inflation Fuels Rate Hike Bets Swiss August inflation doubled to 0.8% year-on-year, exceeding expectations and raising the chance of an earlier SNB rate hike. Higher expected Swiss rates would strengthen the franc. This is a counterforce to the SNB's dovish stance and could push USD/CHF lower if hike bets grow.
This is a key risk to the positive USD/CHF trend: rising inflation could force the SNB to hike, boosting the franc.

July 202618 Jun – 15 Jul 2026

▲2▼2

SNB holds at zero, Fed rate bets and safe-haven flows drive USD/CHF

SNB holds rates at zero, ready to weaken franc The Swiss National Bank kept its key rate at zero and said it is increasingly willing to step into currency markets to stop the franc from getting too strong. That caps the franc and supports USD/CHF, because a central bank that fights franc strength makes holding francs less rewarding.
This is the main policy force keeping a floor under USD/CHF.
Fed rate-hike expectations and safe-haven dollar demand Renewed US-Iran tensions and rising oil prices boosted the safe-haven dollar, while Fed minutes showed some officials open to a rate hike and markets priced a 62% chance of a September increase. Higher expected US rates pull money into dollars, lifting USD/CHF.
This explains the dollar side of the pair and the recent push higher.
Weak US jobs and inflation data weigh on the dollar A weak US Nonfarm Payrolls report and slower June Producer Price Index growth, plus dovish comments from Fed officials, pushed the dollar down and USD/CHF to around 0.8034. Softer US data reduce the chance of Fed rate hikes, which weakens the dollar against the franc.
This is the main counterweight pulling USD/CHF lower.
AI-driven hedging flows support the franc Bank of America says currency hedging tied to the AI stock boom is now a bigger FX driver than usual fundamentals, and these flows have generally supported the Swiss franc while putting modest selling pressure on the dollar. That works against USD/CHF.
It is a structural flow that adds to franc strength, a real counterweight.

18 Jun – 15 Jul 2026

▲2▼2

SNB holds at zero, Fed rate bets and safe-haven flows drive USD/CHF

SNB holds rates at zero, ready to weaken franc The Swiss National Bank kept its key rate at zero and said it is increasingly willing to step into currency markets to stop the franc from getting too strong. That caps the franc and supports USD/CHF, because a central bank that fights franc strength makes holding francs less rewarding.
This is the main policy force keeping a floor under USD/CHF.
Fed rate-hike expectations and safe-haven dollar demand Renewed US-Iran tensions and rising oil prices boosted the safe-haven dollar, while Fed minutes showed some officials open to a rate hike and markets priced a 62% chance of a September increase. Higher expected US rates pull money into dollars, lifting USD/CHF.
This explains the dollar side of the pair and the recent push higher.
Weak US jobs and inflation data weigh on the dollar A weak US Nonfarm Payrolls report and slower June Producer Price Index growth, plus dovish comments from Fed officials, pushed the dollar down and USD/CHF to around 0.8034. Softer US data reduce the chance of Fed rate hikes, which weakens the dollar against the franc.
This is the main counterweight pulling USD/CHF lower.
AI-driven hedging flows support the franc Bank of America says currency hedging tied to the AI stock boom is now a bigger FX driver than usual fundamentals, and these flows have generally supported the Swiss franc while putting modest selling pressure on the dollar. That works against USD/CHF.
It is a structural flow that adds to franc strength, a real counterweight.